Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS

Jasper Therapeutics, Inc.

2024-Q3 EPS reported -$3.25

Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.
SPOTLIGHT study: 93% clinical response (83% complete response) in 120mg cohort; no SAEs.
Initial BEACON data in CSU expected week of Jan 6, 2025; asthma challenge study cleared in Canada/EU.
Discontinued LR-MDS program as briquilimab did not improve hematopoiesis.
R&D expenses $14.5M, G&A $5.4M for Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.